First-line treatment with nivolumab plus ipilimumab or pembrolizumab were the more cost-effective options for newly diagnosed advanced melanoma with unknown BRAF pathogenic variant status, a cost-utility analysis reveals. The analysis was done by Dr. Lizheng Shi, the interim chair of the...